BackIntegra Lifesciences Holdings Overview
Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Target Price

Analysts' average 12-month price target for Integra Lifesciences Holdings is $21.

Get informed when a big investor buys or sells

+ Follow

Share Price

$16.72

Average Target Price

$20.5022.6% upside

4 analysts in the last 4 months

High: $25 | Low: $19

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-28UBS$1913.6% upsideOpen
2026-07-16Truist Financial$1913.6% upsideOpen
2026-07-08BMO Capital$1913.6% upsideOpen
2026-06-18Argus Research$2549.5% upsideOpen
2026-04-15Truist FinancialRichard Newitter$1228.2% downsideOpen
2025-10-15Truist Financial$1510.3% downsideOpen
2024-10-07BTIGRyan Zimmerman$2019.6% upsideOpen
2024-07-30Truist FinancialRichard Newitter$2655.5% upsideOpen
2024-07-30CitigroupJoanne Wuensch$2337.6% upsideOpen
2024-07-29BTIGRyan Zimmerman$2231.6% upsideOpen
2024-07-16Truist FinancialRichard Newitter$3291.4% upsideOpen
2024-05-07Truist FinancialRichard Newitter$2549.5% upsideOpen
2024-05-07JMP SecuritiesDavid Turkaly$40139.2% upsideOpen
2024-05-06Wells FargoVik Chopra$2549.5% upsideOpen
2022-10-26Piper SandlerMatt O'Brien$50199% upsideOpen
2022-07-28Piper SandlerFY22 EPS$55228.9% upsideOpen
2021-05-20JefferiesAnthony Petrone$86414.4% upsideOpen
2021-04-29RBC CapitalShagun Singh Chadha$74342.6% upsideOpen
2021-04-29Wells FargoLarry Biegelsen$74342.6% upsideOpen

Integra Lifesciences Holdings (IART) FAQ

Integra Lifesciences Holdings's target price stands at $21. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $21 for IART implies 22.6% upside versus today's price ($16.72). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Integra Lifesciences Holdings's target price evolved across reporting periods, while the comparison chart places IART next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Integra Lifesciences Holdings's reading of $21 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.